Will CervoMed stock go up?

According to Danelfin AI, CervoMed has today an AI Score of 2/10 (Strong Sell rating), because its probability of beating the market in 3 months (42.36%) is -8.46% vs. the average probability (50.82%) of all US-listed stocks.

What is the target price for CervoMed stock?

The CervoMed target price is $20.73 (1Y), according to the average price target offered by analysts.

Is it a good time to buy, sell, or hold CervoMed stock right now?

CervoMed has today a Strong Sell rating (AI Score 2/10), according to Danelfin AI. Its probability of beating the market in 3 months (42.36%) is -8.46% vs. the average probability (50.82%) of all US-listed stocks, based on our AI-powered analysis. You can find more details on whether CervoMed stock is a good buy .

Is CervoMed undervalued right now?

Based on analysts, the average price target upside for CervoMed is +458.74% (1Y). According to Danelfin AI, CervoMed has today an AI Score of 2/10 (Strong Sell Rating).

What was the price range of CervoMed stock over the past 12 months?

The CervoMed stock price range over the past 12 months has been $2.25 - $10.69.

What is going on with CervoMed stock in the last 3 months?

The CervoMed stock performance in the last quarter has been -5.83%.

Does CervoMed offer dividend payments?

No, CervoMed does not currently pay dividends.

What is the current market capitalization of CervoMed?

CervoMed's market cap is $49.91M, as of 2026-07-02 08:00.

When is the next CRVO earnings report date?

CRVO will publish its next earnings report on 2026-05-18.

CervoMed Inc (CRVO) AI Stock Analysis

Advanced Chart

Custom range

Jul 3, 2025

→

Jul 3, 2026

Custom range

Jul 3, 2025

→

Jul 3, 2026

CRVO AI-Powered Stock Analysis

AI Score Explanation

AI Score

Strong Sell

Fundamental
Technical
Sentiment
Low Risk

According to Danelfin’s proprietary AI model, CervoMed Inc today receives an AI Score of 2/10, which translates to a Sell rating. The stock has a 42% probability of outperforming the market in the next 3 months, which is 9% lower than the average probability of any stock (51%). Among the top impactful features, the only positive contributor is Operating Cash Flow (Qtr Discrete), which adds +1.13% to the probability despite being in the bottom 20% of stocks. On the negative side, the Fundamentals Impact (Long Tail) detracts -1.37%, the Chart Pattern (60d) detracts -0.84%, and the Fear & Greed Index (currently at 31, indicating fear) detracts -0.82%. Other detractors include Plus Directional Indicator (+DI, 90d) in the top 10% (-0.73%), Chart Pattern (504d) (-0.72%), Beginning Cash in the bottom 20% (-0.70%), Maximum Volatility in the top 10% (-0.69%), and several other technical signals. Notable data points include Alpha YTD in the bottom 10% (-0.62 alpha), Performance YTD also in the bottom 10% (-53% return), and Institutional Transactions (3m Change) in the bottom 10% (-14.1% change) — yet the latter two actually contribute positively (+0.40% and +0.47% respectively), suggesting that extreme negative values may signal a potential rebound. However, the overwhelming majority of signals are negative, with Maximum Volatility in the top 10% (13.63) indicating high risk, and Distance from KAMA (20d) in the top 10% suggesting overbought conditions. The overall picture is bearish: the stock faces strong headwinds from weak fundamentals, poor technical patterns, and elevated volatility, resulting in a low AI Score and a Sell rating.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

Earnings Quality+1.13%
Stability and reliability of reported earnings
Growth+0.47%
Expected pace of revenue and earnings expansion

Momentum-5.61%
Direction and strength of recent price movements
Valuation-1.65%
How the stock is priced relative to its fundamentals
Sentiment-0.96%
How analysts and the market view the stock
Volatility-0.74%
How much the stock price tends to fluctuate
Size & Liquidity-0.70%
Company size and trading liquidity
Financial Strength-0.20%
Balance sheet strength and financial resilience
Profitability-0.19%
Profitability and operating efficiency metrics

CRVO probability advantage of beating the market (3M):

-8.46%

AI Score

Strong Sell

CervoMed (CRVO) has an AI Score of 2/10 (Strong Sell) because, according to an overall analysis, it has a probability advantage of -8.46% of beating the market (S&P500) in the next 3 months. This advantage is calculated as the difference between the average probability of any US-listed stock (50.82%) and the probability of CRVO (42.36%) of outperforming the market in the next 3 months, as determined by Danelfin AI’s comprehensive analysis.

Average probability of any US-listed stock of beating the market (3M)50.82%
CRVO probability advantage of beating the market (3M)-8.46%
CRVO probability of beating the market (3M)42.36%

CRVO probability advantage of beating the market (3M): -8.46%

The AI-powered overall analysis of CervoMed (CRVO) is based on the 30 fundamental, technical, and sentiment features that had the greatest impact on stock performance during the last 12 months (alpha signals). These alpha signals explain the probability advantage of CRVO:

Type	Alpha Signal	Current Value	Value Decile Position	Probability Advantage Impact (3M)
Fundamental	Fundamentals Impact (Long Tail)	-	N/A	-1.37%
Fundamental	Operating Cash Flow (Qtr Discrete)	-8.02		+1.13%
Technical	Chart Pattern (60d)	figure_159	N/A	-0.84%
Sentiment	Fear & Greed Index (CNN)	31	N/A	-0.82%
Technical	Plus Directional Indicator (+DI, 90d)	31.26%		-0.73%
Technical	Chart Pattern (504d)	figure_38	N/A	-0.72%
Fundamental	Beginning Cash (Millions)	8.24		-0.70%
Technical	Maximum Volatility	13.63%		-0.69%
Technical	Chart Pattern (90d)	figure_41	N/A	-0.62%
Technical	Distance from KAMA (20d)	0.16%		-0.55%
Technical	Upgrade to unlock			-0.55%
Technical	Upgrade to unlock			-0.51%
Sentiment	Upgrade to unlock			+0.47%
Technical	Upgrade to unlock			-0.45%
Technical	Upgrade to unlock			+0.40%

Rest of Alpha Signals: -1.91%

CRVO probability advantage of beating the market (3M)Total:-8.46%
CRVO AI Score

Significant changes Vs previous day

CRVO Short Trading Parameters

These suggested trading parameters for a 3-month horizon help improve risk management and decision-making.

Entry:$3.71
Horizon: 3 months
Stop Loss:$XXXXXPro (XXXXXPro)
Take Profit:$XXXXXPro (XXXXX
Pro
)

CRVO Proven Sell Signal & Price Forecast

This is the price chart for CRVO from January 2, 2026 until today. The chart indicates, in red, the 96 days when the stock received a Sell/Strong Sell rating (sell signals, AI Score 1 to 3).

Forecast: In the section below, the central dotted line represents the most expected path, while the shaded area indicates the anticipated price range. This is based on previous Sell signals with a 90% confidence level.

Full Track Record

Unlock AI-powered forecast

Closing price (USD)
Sell signals

Forecast:

1 Month
3 Months
6 Months
1 Year

CRVO Average Past Performance & Loss Rate

Three months after its 1644 Sell signals since July 2026, CRVO had an average performance of xxxxxx and a xxxxxx Loss rate (negative performance).

1644 Past CRVO Sell Signals	1 Month Later	3 Months Later	6 Months Later	1 Year Later
Average Performance				-12.35%
Average Alpha				-28.54%
Loss Rate (% Negative Perf.)				74.55%
% Negative Alpha				78.87%

CRVO Frequently Asked Questions

Will CervoMed stock go up?
According to Danelfin AI, CervoMed has today an AI Score of 2/10 (Strong Sell rating), because its probability of beating the market in 3 months (42.36%) is -8.46% vs. the average probability (50.82%) of all US-listed stocks.
What is the target price for CervoMed stock?
Is it a good time to buy, sell, or hold CervoMed stock right now?
Is CervoMed undervalued right now?
What was the price range of CervoMed stock over the past 12 months?
What is going on with CervoMed stock in the last 3 months?
Does CervoMed offer dividend payments?
What is the current market capitalization of CervoMed?
When is the next CRVO earnings report date?

CervoMed Inc Company Profile

CervoMed Inc., a biotech firm in the clinical stage, is primarily engaged in the innovation and distribution of pharmaceutical solutions for neurogenerative diseases. At the forefront of its drug offerings is neflamapimod—an orally ingested, small molecule formulation designed to penetrate the brain for effective treatment against dementia with Lewy bodies (DLB), Alzheimer's disease, frontotemporal dementia, and recovery from ischemic strokes. Additionally, CervoMed Inc. has embarked on developing EIP200—a therapeutic potential for central nervous system disorders—which is currently undergoing early phase experimentation and evaluation. Established in 2010, the company charts its agenda from its main operations base located in Boston, Massachusetts.

Sector:Health Care
Country:United States
Industry:Biotechnology
Address:20 Park Plaza, Suite 424, Boston
Employees:15
Website:cervomed.com

Pros

Unmet medical need in neurodegenerative disease markets

Proprietary intellectual property for drug candidate

Potential for orphan drug regulatory incentives

Differentiated mechanism of action for therapeutic candidate

Leverage of prior clinical data for development pathway

Cons

High clinical trial failure rates for drug candidates

Substantial capital requirements for pharmaceutical R&D

Lengthy and uncertain regulatory approval processes

Competition from established pharmaceutical pipelines

Concentration risk on a single primary drug asset

Company	AI Score	Compare
MNOVMediciNova Inc
NMRANeumora Therapeutics Inc
NGENNervGen Pharma Corp
ZVRAZevra Therapeutics Inc
INMInMed Pharmaceuticals Inc

Company	AI Score	Compare
MNOVMediciNova Inc
NMRANeumora Therapeutics Inc
NGENNervGen Pharma Corp
ZVRAZevra Therapeutics Inc
INMInMed Pharmaceuticals Inc

CRVO Stock AI Analysis High Risk

CervoMed Inc

CRVO Stock AI Analysis

CervoMed Inc

CRVO AI-Powered Stock Analysis

AI Score Explanation

AI Score Explanation

Generating AI Score explanation

AI Score Alpha Factors

Alpha Signals: What Drives the AI Score

CRVO probability advantage of beating the market (3M): -8.46%

CRVO Short Trading Parameters

CRVO Proven Sell Signal & Price Forecast

CRVO Average Past Performance & Loss Rate

CRVO Frequently Asked Questions

Will CervoMed stock go up?

What is the target price for CervoMed stock?

Is it a good time to buy, sell, or hold CervoMed stock right now?

Is CervoMed undervalued right now?

What was the price range of CervoMed stock over the past 12 months?

What is going on with CervoMed stock in the last 3 months?

Does CervoMed offer dividend payments?

What is the current market capitalization of CervoMed?

When is the next CRVO earnings report date?

CervoMed Inc Company Profile

Pros

Cons

Pros

Cons

CRVO Company Profile Summary

CRVO Related Investment Themes

CRVO Related Stocks

CRVO Top 10 Industry Stocks

Biotechnology

CRVO Top 10 Sector Stocks

Health Care

CRVO Stock AI Analysis High Risk

CervoMed Inc

NASDAQ NMS - GLOBAL MARKET

Will CervoMed stock go up?

What is the target price for CervoMed stock?

Is it a good time to buy, sell, or hold CervoMed stock right now?

Is CervoMed undervalued right now?

What was the price range of CervoMed stock over the past 12 months?

What is going on with CervoMed stock in the last 3 months?

Does CervoMed offer dividend payments?

What is the current market capitalization of CervoMed?

When is the next CRVO earnings report date?

Pros

Cons

AI Score Explanation

NASDAQ NMS - GLOBAL MARKET

CRVO Proven Sell Signal & Price Forecast